Socialized Medicine Strikes Again! Patients Needlessly Suffer
"To make progress we need to look at investing more money to hasten the implementation of the Cancer Strategy; we need to speed up, not slow down, patient access to cost-effective medicines in the NHS and we need to create a more ambitious plan for using real-world evidence to shine a light on cancer treatment outcomes."07/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2017 Category: Urology & Nephrology Source Type: news

Two Short Quizzes Reveal What You Know About Kidney Cancer
A donation to support the work of young investigators is made for each quiz taken. There is a ten-question quiz and a one-question quiz. Each takes less than a minute to complete. See how you compare to others!07/18/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 18, 2017 Category: Urology & Nephrology Source Type: news

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of FOTIVDA ® (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC). EUSA's marketing authorisation application included data from the TiVO-1 pivotal study, which included over 500 patients with advanced RCC.07/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2017 Category: Urology & Nephrology Source Type: news

Kidney cancer drug approved for NHS use in England
A drug which could prolong life for people with advanced kidney cancer has been approved for use on the NHS in England and Wales.07/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2017 Category: Urology & Nephrology Source Type: news

Considering a Clinical Trial? Phase II Clinical Study of Lenvatinib
Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.06/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 17, 2017 Category: Urology & Nephrology Source Type: news